| Document |
Document Title |
|
WO/2020/083373A1 |
Disclosed is a large-scale magnetic purification system, comprising: a liquid storage device capable of being connected to a liquid source and a waste liquid barrel through a liquid path system; a stirring system installed above the liqu...
|
|
WO/2020/077781A1 |
Disclosed is a preparation method for the synthesis of a polypeptide containing two pairs of disulfide bonds, wherein the method uses oxidation reaction to synthesize a linear peptide into a polypeptide having two pairs of disulfide bond...
|
|
WO/2020/081510A1 |
Described herein are aptamers capable of binding to immunoglobulin G (IgG); compositions comprising an IgG binding aptamer with an IgG protein; and methods of making and using the same. Provided herein are also methods of releasing prote...
|
|
WO/2020/078254A1 |
Provided is a method for isolating recombinant human growth hormone (OsrhGH) from genetically engineered rice and purifying same. The method comprises the following steps: 1) extracting a crude protein extract containing recombinant huma...
|
|
WO/2020/077927A1 |
A post-processing method for a GnRH antagonist, comprising the following steps: (1) preparing before nanofiltration, installing a nanofiltration membrane, using purified water to clean a nanofiltration machine, and preparing nanofiltrati...
|
|
WO/2020/077991A1 |
The present invention falls within the field of biotechnology, and particularly relates to a bifunctional fusion protein platform used for drug research and development, a preparation method therefor and the use thereof. Provided is a bi...
|
|
WO/2020/079108A1 |
The present invention relates to a process for purifying C1-esterase inhibitor (C1-INH), and more in particular a C1-INH concentrate.
|
|
WO/2020/081599A1 |
Disclosed is a chromatographic method for separating a mixture of compounds having ionizable groups using a mobile phase comprising (a) a first mobile phase component comprising an aqueous buffer system and an organic solvent mixture mis...
|
|
WO/2020/079211A1 |
The present invention relates to an electrophoresis assembly, particularly useful for performing high-throughput electrophoresis, as well as to methods for performing electrophoresis. Also disclosed is a frame for holding a separation ma...
|
|
WO/2020/075670A1 |
The purpose of the present invention is to provide a solid-phase support on which an IgG-binding peptide is immobilized, the peptide being usable for IgG purification, having resistance to repeated washing with an alkaline solution after...
|
|
WO/2020/073486A1 |
Pea oligopeptide selenium, a preparation method therefor, and application thereof. The pea oligopeptide selenium is subjected to digestion treatment in at least one of the following three modes, the selenium content changing by not more ...
|
|
WO/2020/074483A1 |
The present invention relates method for purifying antibodies, said method comprising a limited number of steps while still allowing obtaining high yields of purified antibodies with an appropriate degree of purity. Briefly, this method ...
|
|
WO/2020/070587A1 |
The present application relates to methods for producing structurally variant polypeptide molecules in parallel using column-free techniques by polypeptide ligation, separation of ligated polypeptides from ligation reactions, folding of ...
|
|
WO/2020/069718A1 |
The present disclosure relates to RNA particles for delivery of RNA to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration, an...
|
|
WO/2020/070040A1 |
The present disclosure relates to RNA particles for delivery of RNA to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration, an...
|
|
WO/2020/062782A1 |
The present invention relates to a complete liquid-phase synthesis method of sinapultide. The complete liquid-phase synthesis method comprises: firstly, synthesising of Fmoc-Leu-Leu-Leu-Leu-Lys(Boc)-OH, and synthesising of complete prote...
|
|
WO/2020/063216A1 |
A peptoid compound, a method for preparing a peptoid compound, an oligomer, a pharmaceutical composition, a use of a pharmaceutical composition in preparing a medicament for detecting or diagnosing diseases related to tyrosine kinase HER...
|
|
WO/2020/068432A1 |
Disclosed herein are compositions comprising extracellular matrix proteins produced by small mobile stem cells, and systems comprising the composition. Also disclosed are methods of making the compositions and systems, and methods of usi...
|
|
WO/2020/066270A1 |
The purpose of the present invention is to provide a method for producing a κ chain variable region-containing antibody and/or antibody fragment at a high purity by efficiently separating the κ chain variable region-containing antibody...
|
|
WO/2020/068135A1 |
A chromatography column has a column assembly that further includes a column jacket tube and a column liner tube. The column assembly is configured with end fittings that have compression limiting features and are able to withstand very ...
|
|
WO/2020/067418A1 |
The present invention addresses the problem of providing a method for producing adeno-associated viral capsid protein useful as an antigen for the production of anti-AAV antibodies. The present invention provides a method for producing a...
|
|
WO/2020/060412A1 |
Disclosed are phosphonate-containing trifunctional crosslinkers and methods for synthesizing same. The invention further pertains to using the trifunctional crosslinkers in methods for crosslinking, purifying, and characterizing biomolec...
|
|
WO/2020/056790A1 |
Disclosed in the present invention is a monoclonal antibody that specifically binds human and monkey CD38 antigens or a derivative thereof, comprising antigen complementarity-determining regions CDR1, CDR2 and CDR3 of an antibody light c...
|
|
WO/2020/058277A1 |
The present invention relates to a method for producing a site-specifically serine ADP-ribosylated protein or peptide being, comprising: (a) subjecting a protein or peptide comprising or consisting of an amino acid sequence comprising tw...
|
|
WO/2020/060087A1 |
The present disclosure relates to a pharmaceutical highly efficient anti-TFPI antibody composition including an anti-TFPI antibody for treating hemophilia, in which the content of HCP in a drug substance is less than 10.0 ng/mg, and the ...
|
|
WO/2020/061251A1 |
Disclosed is a high-throughput method and system for mapping or screening biomolecular interactions, where the method includes providing a plurality of cells, or in some examples purified proteins themselves, expressing a phase separatio...
|
|
WO/2020/057088A1 |
The present invention relates to the technical field of polypeptide synthesis. Disclosed is a method for synthesizing goserelin. The synthesis method comprises: coupling Azagly and resin; sequentially coupling amino acids at an Azagly-re...
|
|
WO/2020/057089A1 |
The present invention belongs to the field of peptide synthesis technology, and disclosed is a method for synthesizing Goserelin, the synthesis method comprising: coupling Azagly and resin to obtain Azagly-resin; coupling amino acids at ...
|
|
WO/2020/061036A1 |
In some embodiments, methods of detecting an association between a query protein and a target moiety are described. In some embodiments, compositions are described. In some embodiments, kits are described.
|
|
WO/2020/053661A1 |
The present disclosure relates to methods of producing antibodies and compositions comprising antibodies from the milk of transgenic non-human mammals, involving precipitation using an acidic chitosan solution.
|
|
WO/2020/053451A2 |
There is provided a method of identifying a resin for isolating or enriching a protein of interest using affinity chromatography. The method comprises the steps of: i) providing the three-dimensional structure of the protein of interest;...
|
|
WO/2020/053272A1 |
A method is provided for separating soluble proteins from chlorophyll using a water-soluble silicate. Various purified products and intermediates are also provided.
|
|
WO/2020/054287A1 |
The present invention provides a method for purifying a target peptide, the method including a step for mixing, in the presence of a sulfonate compound, a solvent with a peptide obtained through peptide synthesis to obtain a solid, and c...
|
|
WO/2020/047994A1 |
Provided is a solid-phase synthesis method of abaloparatide, specifically comprising the step of removing a Fmoc protecting group by using a Fmoc protecting group removal agent on Asp, wherein the removal agent is an AlCl 3 NMP solution ...
|
|
WO/2020/048117A1 |
The present invention provides a purification method for dulaglutide. The method comprises: crushing bacteria expressing dulaglutide, and obtaining filtrate after filtering; extracting the filtrate by using an extractant to collect an or...
|
|
WO/2020/010029A9 |
The present disclosure provides an apparatus for synthesizing a biopolymer, a method for preparing an apparatus for synthesizing a biopolymer, and a method of synthesizing a biopolymer. The apparatus comprises (a) a substrate comprising ...
|
|
WO/2020/051307A1 |
Stabilized formulations for Immunoglobulin A and other biotherapeutic proteins. Formulations comprising at least one pH buffering agent at about pH 5 to about 8, optional non- ionic surfactant, and one or more optional stabilizing agents...
|
|
WO/2020/051566A1 |
Although numerous investigations are focused on developing vaccines that induce protective humoral responses, fewer studies are aimed at developing vaccines that induce broad and robust T cell responses. In order to design a potent T cel...
|
|
WO/2020/046836A1 |
Disclosed herein are compositions comprising fixed doses of ETC- 1002 and Ezetimibe. Also disclosed herien are methods for using fixed doses of ETC- 1002 and Ezetimibe. Uses include methods of treating cardiovascular disease or reducing ...
|
|
WO/2020/043849A1 |
The present invention relates to method for purifying a polypeptide. The present invention more particularly relates to the improved purification a polypeptide of interest from a sample containing said polypeptide of interest and impurit...
|
|
WO/2020/045477A1 |
A method for purifying a polypeptide is provided by which undesired polypeptides can be efficiently removed. The method is for purifying a desired polypeptide by subjecting a sample containing the desired polypeptide and undesired polype...
|
|
WO/2020/045290A1 |
The purpose of the present invention is to provide a method that enables efficient removal of impurities from an impurity-containing aqueous solution or suspension of an antibody or an antibody-like molecule. A method for purifying an an...
|
|
WO/2020/045530A1 |
In the present invention, by connecting a peptide tag having the amino acid sequence below to a target protein and causing the target protein to be expressed, the target protein is efficiently accumulated in a soluble fraction. X(PY)qPZ,...
|
|
WO/2020/045541A1 |
Provided is a chromatography carrier which has a high kinetic binding capacity to a target substance and exhibits excellent performance for separating a target substance from contaminants. This chromatography carrier includes a support b...
|
|
WO/2020/046793A1 |
In situ Raman spectroscopy methods and systems for characterizing or quantifying a protein purification intermediate and/or final concentrated pool during production or manufacture are provided. In one embodiment, in situ Raman spectrosc...
|
|
WO/2020/040307A1 |
Provided is an affinity carrier having improved alkali resistance. This immunoglobulin-binding protein contains a mutant polypeptide chain. This affinity carrier includes a solid-phase carrier to which the immunoglobulin-binding protein ...
|
|
WO/2020/041557A1 |
This invention relates to protein-based adhesives that are capable to adhere to a substrate in a dry, wet, moist, or an aqueous environment. Particularly, said adhesives comprise a crosslinking agent and an elastin-like polypeptide (ELP)...
|
|
WO/2020/041799A1 |
Disclosed herein are compositions comprising fixed doses of ETC-1002, ezetimibe, and statin, and methods of treating subjects comprising adminstering fixed doses of ETC-1002, ezetimibe, and statin. Also disclosed herein are methods for a...
|
|
WO/2020/039339A1 |
The present invention relates to a process for purification of non‐glycosylated insulin analogues 5 from a mixture comprising glycosylated and non‐glycosylated proteins by removal of glycosylated proteins. The removal is achieved by ...
|
|
WO/2020/038954A1 |
The disclosure relates to a method for pre-analytical treatment of a serum or plasma sample from a patient suspected of suffering from oxidative stress, the method comprising contacting said sample with one or more microcapsules having a...
|
